MedTrace Logo

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT07277413 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2026-04-03

No results posted yet for this study

Summary

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Conditions

  • NSCLC Adenocarcinoma
  • Gastroesophageal Cancer (GC)
  • Gastric Adenocarcinoma
  • Adenocarcinoma of Esophagus
  • Squamous Cell Car. - Esophagus
  • Urothelial Carcinoma (UC)
  • Bladder Cancer
  • Mesothelioma
  • Pleural Mesothelioma
  • Peritoneal Mesothelioma
  • Non-Small Cell Lung Cancer NSCLC

Interventions

DRUG

IDE892

IDE892 is an inhibitor of the Protein arginine methyltransferase 5 (PRMT5) that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions.

DRUG

IDE397

IDE397 is an oral MAT2A inhibitor that is being developed by IDEAYA Biosciences, Inc. as an anticancer therapeutic for patients with advanced or metastatic cancer harboring MTAP deletions. In this study, IDE397 will be evaluated in combination with IDE892 (Parts 3 and 4) in participants with MTAP-deleted advanced solid tumors.

Sponsors & Collaborators

  • IDEAYA Biosciences

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-04
Primary Completion
2028-04-30
Completion
2028-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07277413 on ClinicalTrials.gov